Efficacy of Sacubitril-Valsartan in heart failure patients with and without an implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy (CRT).

Trial Profile

Efficacy of Sacubitril-Valsartan in heart failure patients with and without an implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy (CRT).

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 New trial record
    • 30 Aug 2017 Results assessing efficacy Sacubitril-Valsartan in heart failure patients with and without an implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy (CRT), were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top